Skip to main content

Table 2 Background, characteristics and diagnosis methods for hepatocellular carcinoma

From: The efficacy of contrast protocol in hepatic dynamic computed tomography: multicenter prospective study in community hospitals

   Protocol-A Protocol-B Protocol-C Protocol-D
Background*
  Hepatitis B   5 (3.5) 8 (6.8) 6 (6.9) 6 (9.0)
  Hepatitis C   36 (25.0) 35 (29.9) 17 (19.5) 19 (28.4)
  LC   104 (72.2) 75 (64.1) 65 (74.7) 42 (62.7)
      LC-B   9 (6.3) 8 (6.8) 3 (3.4) 2 (3.0)
      LC-C   75 (52.1) 51 (43.6) 45 (51.7) 28 (41.8)
      LC-Alcoholic   13 (9.0) 9 (7.7) 11 (12.6) 13 (19.4)
      NASH   5 (3.5) 1 (0.9) 0.(0.0) 0 (0.0)
      Others   5 (3.5) 9 (7.7) 8 (9.2) 2 (3.0)
  Fatty liver   1 (0.7) 0 (0.0) 3 (3.4) 2 (3.0)
  Others   2 (1.4) 2 (1.7) 0 (0.0) 0 (0.0)
Characteristics
  Size of tumor** (mm)   17.08 ± 6.42 16.85 ± 5.88 16.70 ± 6.27 16.60 ± 6.29
      Range   3.0-30.0 5.6-30.0 7.0-30.0 6.6 − 29.0
  <20 mm 89 (61.8) 73 (62.4) 62 (71.3) 45 (67.2)
  >20 mm 55 (38.2) 44 (37.6) 25 (28.7) 22 (32.8)
  Number of tumors 1-3 109 (75.7) 97 (82.9) 65 (74.7) 47 (70.1)
  4-6 14 (9.7) 8 (6.8) 7 (8.0) 6 (9.0)
  7-9 6 (4.2) 3 (2.6) 1 (1.1) 4 (6.0)
  >10 15 (10.4) 9 (7.7) 14 (16.1) 10 (14.9)
Diagnosis methods*
  Biopsy   5 (3.5) 1 (0.9) 0 (0.0) 0 (0.0)
  CE-MRI   33 (22.9) 39 (33.3) 31 (35.6) 14 (20.9)
  CTAP/CTHA   10 (6.9) 9 (7.7) 10 (11.5) 9 (13.4)
  Angiography   29 (20.1) 43 (36.8) 10 (11.5) 26 (38.8)
  Lipiodol CT   12 (8.3) 15 (12.8) 4 (4.6) 3 (4.5)
  Sonography   42 (29.1) 56 (47.9) 40 (46.0) 28 (41.8)
  Growth of tumor   45 (31.3) 27 (23.1) 37 (42.5) 11 (16.4)
  Increased tumor markers   78 (54.2) 70 (59.8) 45 (51.7) 34 (50.7)
  1. Note; Data presented as number (%) of patients or mean ± standard deviation (SD);
  2. LC, Liver cirrhosis; NASH, non-alcoholic steatohepatitis, CE-MRI, Contrast-enhanced magnetic resonance imaging;
  3. CTAP, computed tomography during arterial portography; CTHA, computed tomography during hepatic arteriography
  4. ** Background and diagnosis methods were made by multiple selections.
  5. * Tumor selected as target tumor for quantitaive analysis.